IDEAYA Biosciences, Inc. IDYA Darovasertib — External Clinical Development Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by IDEAYA Biosciences, Inc. in its filing.
Tagged under the XBRL concept idya:ExternalClinicalDevelopmentExpenses.
The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about IDEAYA Biosciences, Inc.'s darovasertib — external clinical development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is IDEAYA Biosciences, Inc.'s darovasertib — external clinical development expenses?
- IDEAYA Biosciences, Inc. (IDYA) reported darovasertib — external clinical development expenses of $23.33M in Q1 2026.
- How has IDEAYA Biosciences, Inc.'s darovasertib — external clinical development expenses changed year-over-year?
- IDEAYA Biosciences, Inc.'s darovasertib — external clinical development expenses increased by 1.4% year-over-year, from $23.02M to $23.33M.
- What is the long-term trend for IDEAYA Biosciences, Inc.'s darovasertib — external clinical development expenses?
- Over 3 years (2022 to 2025), IDEAYA Biosciences, Inc.'s darovasertib — external clinical development expenses has grown at a 94.1% compound annual growth rate (CAGR), from $13.43M to $98.24M.
- What does darovasertib — external clinical development expenses mean?
- This metric represents the direct, third-party costs incurred to conduct clinical trials and research activities specifically associated with the Darovasertib therapeutic candidate. It captures outsourced expenditures such as contract research organization fees, clinical site payments, and laboratory testing costs required to advance the drug through regulatory development phases. Monitoring this figure provides insight into the capital intensity and development velocity of the company's lead oncology pipeline asset.